기본 정보
- CAS
36507-48-9- 표준 SMILES
CC(C)(C)NC[C@H](O)COc1ccccc1C1CCCC1- InChIKey
KQXKVJAGOJTNJS-HNNXBMFYSA-N- 분자식
- C18H29NO2
- 평균 분자량
- 291.4 g/mol
- 단동위원소 질량
- 291.21982917
개요
Penbutolol is a member of ethanolamines.
이름 및 식별자
- 우선 이름
- Penbutolol
- IUPAC
- (2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol
- 현지명
- 펜부톨롤
- 영어명
- Penbutolol
- 분자식
- C18H29NO2
- 분자량
- 291.43
이름 및 동의어
penbutolol(-)-Penbutolol38363-40-5Penbutololum(2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-olCHEBI:795478W62V43DYDTXSID80234282-Propanol, 1-(2-cyclopentylphenoxy)-3-((1,1-dimethylethyl)amino)-tert-butyl[(2S)-3-(2-cyclopentylphenoxy)-2-hydroxypropyl]aminepenbutololotert-butyl((2S)-3-(2-cyclopentylphenoxy)-2-hydroxypropyl)amine
이름 더 보기
펜부톨롤C07416HOE 893HOE 893DLevopenbutolLevopenbutolol(-)-(S)-Penbutolol
RefChem:859296DTXCID903428C07AA23(s)-penbutololBetapressinPenbutolol (INN)(-)-Isopenbutololl-Penbutolol
데이터베이스 식별자
- CAS
36507-48-9、38363-40-5- PubChem CID
- 37464
- DTXSID
DTXSID8023428- ChEMBL
CHEMBL1290、CHEMBL87418- ChEBI
물성
구조 계산 물성
- XLogP
- 4.2
- 극성 표면적
- 41.5 Ų
- 수소 결합 공여자 수
- 2
- 수소 결합 수용자 수
- 3
- 회전 가능 결합 수
- 7
- 무거운 원자 수
- 21
- 형식 전하
- 0
- 복잡도
- 294
실험 및 물리화학적 성질
DrugsPharmaceuticals -> Listed in ZINC15
LogP
4.15
3.61
Solubility2.12e-02 g/L
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics
Pharmaceuticals
Physical DescriptionSolid
Dissociation Constants9.92
물리화학적 성질
- 녹는점
- 68 · 68-72°
- 끓는 점
- 433.43 °C · 433.43°C (rough estimate)
- 밀도
- 1.0344 · 1.0344 (rough estimate)
- 굴절률
- 1.5 · 1.5000 (estimate)
- 산도 계수 (pKa)
- 9.3 · 9.3 (1.5 mmol/l in 25% ethanol)
- 색상
- 크리스탈
- 수용성
- 7 g/L · 7g/L(상온)
안전 및 규제
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
독성 정보
Hepatotoxicity
Mild-to-moderate elevations in serum aminotransferase levels occur in less than 2% of patients on penbutolol and are usually transient and asymptomatic, resolving even with continuation of therapy. Despite its wide spread use, penbutolol has not been convincingly linked to instances of clinically apparent liver injury. Other beta-blockers have been linked to rare instances of acute liver injury with a latency to onset of 4 to 24 weeks, a hepatocellular pattern of serum enzyme elevations and a rather mild, self-limiting course without evidence of hypersensitivity or autoimmune reactions.
Drug Induced Liver Injury
Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)
penbutolol
Levatol®
Beta blockers
Not Applicable
no-DILI-concern
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
안전 데이터
- 독성
- LD50 oral in rabbit: 300mg/kg
- 기존화학 물질
- KE-09314
화학 및 산업
약리 정보
ATC Code
C - Cardiovascular system
QC - Cardiovascular system
Protein Binding80-98% bound to plasma proteins. Extensively bound to Alpha-1-acid glycoprotein 1.
Pharmacodynamics
Penbutolol is a ß-1, ß-2 (nonselective) adrenergic receptor antagonist. Experimental studies showed a dose-dependent increase in heart rate in reserpinized (norepinephrine-depleted) rats given penbutolol intravenously at doses of 0.25 to 1.0 mg/kg, suggesting that penbutolol has some intrinsic sympathomimetic activity. In human studies, however, heart rate decreases have been similar to those seen with propranolol.
Mechanism of Action
Penbutolol acts on the β1 adrenergic receptors in both the heart and the kidney. When β1 receptors are activated by catecholamines, they stimulate a coupled G protein that leads to the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The increase in cAMP leads to activation of protein kinase A (PKA), which alters the movement of calcium ions in heart muscle and increases the heart rate. Penbutolol blocks the catecholamine activation of β1 adrenergic receptors and decreases heart rate, which lowers blood pressure.
Biological Half-LifePlasma= approximately 5h Conjugated= approximately 20h in healthy persons, 25h in healthy elderly persons, and 100h in patients on renal dialysis.
Metabolism/MetabolitesMetabolized in the liver by hydroxylation and glucuroconjugation forming a glucuronide metabolite and a semi-active 4-hydroxy metabolite.
FDA Pharmacological Classification
78W62V43DY
PENBUTOLOL
Mechanisms of Action [MoA] - Adrenergic beta-Antagonists
Established Pharmacologic Class [EPC] - beta-Adrenergic Blocker
Penbutolol is a beta-Adrenergic Blocker. The mechanism of action of penbutolol is as an Adrenergic beta-Antagonist.
관련 반응
0건
현재 필터 조건에 해당하는 반응 기록이 없습니다.
화합물 노트
불러오는 중…